COMP <GO>
HCA vs LLY // EV/EBITDA & P/E VALUATION
HCA Healthcare Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: HCA 5
— LLY 10
▲ EV/EBITDA & P/E VALUATION LEADER: HCA
LAST: $473.19 (-1.02%) • MKT CAP: $103.51B
valuation
11.5x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCA VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCA | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.90% | 32.36% | -13.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 11.5x | 36.4x | -24.92 | HCA | /valuation <GO> |
| Free Cash Flow Yield | 7.43% | 2.30% | +5.13 | HCA | /fcf-yield <GO> |
| Operating Margin | 10.90% | 40.21% | -29.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 31.90% | -22.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 7.10% | 45.51% | -38.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.66% | 0.49% | +0.17 | HCA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.68 | 9.29 | -5.61 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.77% | +0.23 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.7 | 77.9 | -17.19 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.51 | +0.53 | HCA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 14.2x | 26.3x | -12.05 | HCA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $103.51B | $1.33T | -$1.23T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCA REV | LLY REV | HCA GROSS % | LLY GROSS % | HCA FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $75.60B | $65.18B | 44.0% | 83.0% | $7.69B | $16.81B |
| FY 2024 | $70.60B | $45.04B | 44.0% | 81.3% | $5.64B | $8.82B |
| FY 2023 | $64.97B | $34.12B | 44.0% | 79.3% | $6.51B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCA // BETA 1.04
LLY // BETA 0.51